07329671 is referenced by 76 patents and cites 162 patents.

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Title
2,4-pyrimidinediamine compounds and their uses
Application Number
11/148746
Publication Number
7329671 (B2)
Application Date
June 8, 2005
Publication Date
February 12, 2008
Inventor
Alexander B Rossi
San Francisco
CA, US
Hui Li
Millbrae
CA, US
Catherine Sylvain
Burlingame
CA, US
Somasekhar Bhamidipati
Foster City
CA, US
Holger Keim
Menlo Park
CA, US
Jeffrey Clough
Redwood City
CA, US
Sacha J Holland
San Francisco
CA, US
Susan Molineaux
San Mateo
CA, US
Donald Payan
Hillsborough
CA, US
Ankush Argade
Foster City
CA, US
Rajinder Singh
Belmont
CA, US
Agent
Brian D Griedel
James J Diehl
Foley & Lardner
Assignee
Rigel Pharmaceuticals
CA, US
IPC
A01K 31/55
A01N 43/54
View Original Source